UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant decline in short interest in the month of April. As of April 30th, there was short interest totaling 201 shares, a decline of 82.7% from the April 15th total of 1,164 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 107,071 shares, the short-interest ratio is currently 0.0 days.

UCB Stock Down 0.3%

OTCMKTS UCBJY opened at $137.79 on Tuesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. UCB has a 1 year low of $84.94 and a 1 year high of $168.76. The business’s 50-day moving average is $147.03 and its 200 day moving average is $145.26.

Analyst Ratings Changes

Several research analysts have recently commented on UCBJY shares. Zacks Research upgraded UCB from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 14th. Wolfe Research upgraded UCB to a “strong-buy” rating in a report on Monday, February 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Strong Buy”.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.